FIMECS Organizes 2nd Targeted Protein Degradation Conference in Japan
News release Download PDF
Kanagawa, Japan, 28th March 2023 – FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on Targeted Protein Degradation (“TPD”), today announces that FIMECS organizes an international conference, the 2nd Targeted Protein Degradation Conference in Japan (26th-27th July 2023, Shonan Health Innovation Park, Kanagawa, Japan). TPD is well known as PROTAC and molecular glue, and unveiling next-generation strategies such as AUTAC, LYTAC, TRAFTAC, RIBOTAC, RIPTAC, DUBTAC, and more. FIMECS invites worldwide top-tier scientists from industry and academia to speak about their TPD research at the conference. The conference definitely gives you wonderful opportunities for networking as well as to learn more about the very latest. Additionally, FIMECS believes that the conference contributes to activating and growing TPD research in Asia.
For more information and registration: https://conference.fimecs.com/
About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDSTM platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects. https://www.fimecs.com/eng/
RaPPIDSTM (Rapid Protein Proteolysis Inducer Discovery System) is one of the proprietary drug discovery platforms of FIMECS, Inc. used to generate therapeutic candidates of the targeted protein degrader. The platform allows synthesizing and evaluating various degraders quickly based on the company’s proprietary know-how and diversity-oriented synthesis, and delivery of the drug candidates with the best combination of target protein binders, linkers, and E3 ligase binders. Moreover, RaPPIDSTM platform enables the discovery of novel E3 ligase binders, which is expected to dramatically expand the range of target proteins that can be degraded.
# # #
The Conference Contact:
Steering Committee of the 2nd Targeted Protein Degradation Conference in Japan C/O ibma Co., Ltd.
Ebisu-West 4F, 1-16-15 Ebisu-nishi, Shibuya-ku, Tokyo, 150-0021, Japan
FIMECS, Inc. Media and Investor Contact:
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan